Turku, Finland – 14 September 2022: – DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland, today announced that it has received an approval to start a first-in-man clinical study with its in-house controlled-release eye drops utilizing DelSiTech™ Silica Matrix technology. The clinical study will be conducted in Finland and its main objectives are to evaluate the safety and tolerability of the product in healthy volunteers.

Dr. Lasse Leino, CEO of DelSiTech commented: “We are very excited to reach this milestone. Starting a clinical trial with our own product is an important achievement for DelSiTech to become a clinical stage drug development company. This will be the very first time that silica-based eye drops are applied topically in human subjects, thanks to our persistent work to develop this product and the silica eye drop delivery platform in general. Long-acting eye drops represent a new way to administer topical products in the eye. Less frequent dosing such as once-a-day or even once every other day improves patient compliance and enhances the effectiveness of many topical eye treatments. Currently, there is strong interest in DelSiTech™ Silica Matrix technology in ophthalmology which is evidenced by our recent collaboration and license agreement with a Swiss drug development company on controlled release dexamethasone eye drops.”